CCL5 as a potential immunotherapeutic target in triple-negative breast cancer. - Wikidata - wikimedia - TriplyDB

CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

http://www.wikidata.org/entity/Q37729639

about

Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells Elevated expression of myosin X in tumours contributes to breast cancer aggressiveness and metastasis.Loss of PPARγ expression in mammary secretory epithelial cells creates a pro-breast tumorigenic environment.Heterogeneity of functional properties of Clone 66 murine breast cancer cells expressing various stem cell phenotypes Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.Didymin reverses phthalate ester-associated breast cancer aggravation in the breast cancer tumor microenvironment Mesenchymal stem cell-derived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation of matrix metalloproteinases.Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5.The inflammatory chemokine CCL5 and cancer progression Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.Macrophage Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in Breast Cancer.Lactobacillus paracasei strain 06TCa19 suppresses inflammatory chemokine induced by Helicobacter pylori in human gastric epithelial cells.Poly (I:C) enhances the anti-tumor activity of canine parvovirus NS1 protein by inducing a potent anti-tumor immune response.Irreversible electroporation inhibits pro-cancer inflammatory signaling in triple negative breast cancer cells.CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis.The RNA-binding protein HuR inhibits expression of CCL5 and limits recruitment of macrophages into tumors.Sox2 Communicates with Tregs Through CCL1 to Promote the Stemness Property of Breast Cancer Cells.CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells.Human Placental-Derived Adherent Stromal Cells Co-Induced with TNF-α and IFN-γ Inhibit Triple-Negative Breast Cancer in Nude Mouse Xenograft Models.Forensic Potential of MMPs and CC Chemokines for Wound Age Determination.Viral manipulation of STAT3: Evade, exploit, and injure.Identification of an acid sphingomyelinase ceramide kinase pathway in the regulation of the chemokine CCL5.Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4

P2860

Q26784324-E4C951E8-B4F8-42A8-B30B-E9833D10E505 Q31814868-54B49B9E-CF3C-4DB0-B694-FFB0FFBFA103 Q33994291-B2B19DF2-1888-4F91-961F-D1C90B591468 Q34522002-0BBDD1BB-6584-41FB-B78E-91CE4A19D3CE Q35050347-8454461C-9655-48BE-B971-A5971B839FA7 Q35744895-07C6AD2D-690F-4B23-8359-FDEEE3D071CF Q35799094-F557F08E-1BDE-4F75-A15C-32D4109257D6 Q36524400-17332094-F55B-41EB-90A1-F4D668E2287B Q37014822-E23EDBC9-D234-45E1-8F16-2D9EB6DCB1A3 Q37269350-92FE38C4-C0D7-4988-BA01-2CB6A49303D2 Q37541911-4B10C664-DAB3-496F-B850-FC6036972DA8 Q38756385-379A02FD-61B0-4B37-926B-96B487AB1929 Q39096364-7837CA36-EB82-4160-88DD-BEBA8D72E6EE Q40241221-B066EF80-0AF5-40EB-8596-BC8B108EA25E Q40516283-033A3765-7805-4F69-BE13-CCC37F4B9272 Q45044080-E4DA8983-1C6C-448E-863E-036262A1F92F Q47144882-C32B1453-3436-41A1-A436-7B18AA85E3C5 Q48088391-6A66DAAA-0EC4-489A-ABFA-8D96E872D2DE Q48167950-12AD4B03-0D98-475C-B966-AA7378223C07 Q48527882-73F56B38-92C8-4F83-9E4A-953D6E2CFC84 Q50058491-40D4ADA5-1A99-4285-B8FF-8D51D6C0BCAE Q53396323-737A7A52-FFC4-4128-97D7-A79940E4E988 Q54255379-12043564-5BB6-4E19-B3D7-EF90B0959243 Q54979802-0857B029-81B0-431D-B7FB-E82F01AE96A6 Q58792549-F580BF76-07B1-4CCD-A5D4-7291F67F7E08

P2860

CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

http://www.wikidata.org/entity/Q37729639

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 February 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

@en

CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

@nl

type

label

CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

@en

CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

@nl

prefLabel

CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

@en

CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

@nl

P1433

Q37729639-88616B97-C280-4442-816D-37420027933C

P1476

Q37729639-FA870ACE-279E-4EE5-AAE3-F178C7277071

P2093

Q37729639-7C568BDD-8E30-4012-B262-3CBAB039AE12

Q37729639-940FDF38-7A70-4CE7-8BBC-EE25A9F0BCC8

Q37729639-9CCDF632-D01E-4AEE-BA6C-8D47B49C6B1B

Q37729639-BA80168E-30E7-4DE6-B463-045C20B8FFB2

Q37729639-CA5FD1CD-B3E8-496D-9DB0-76186B85538E

P2860

Q37729639-025F2C2A-4A68-464F-AF14-A19A4A32B901

Q37729639-12197161-8A4C-4AC4-82C1-A0D6C502B463

Q37729639-1A1AF392-B929-4067-83B4-1E8D50FD33D7

Q37729639-1CDE5F97-A29E-4550-83F5-533993D4144E

Q37729639-1D21F0BD-3C63-4358-9DAB-5FF0BBD3AE7F

Q37729639-29327BB9-06D5-4F2C-80DB-813CA65C6849

Q37729639-2B1657E3-40AF-4BA2-9923-554B476A6BB7

Q37729639-2E00A217-7CFA-4034-82E2-971118387141

Q37729639-337294C9-097F-4EC4-B73E-41257EA1B21E

Q37729639-35ADC28F-C370-4DAE-A126-B95D618B50BA

P2888

Q37729639-BA7225ED-FC7F-4108-96EC-AEE2532E9DB4

P304

Q37729639-2CA27FDE-8695-4DA9-9A03-4DF07E187264

P31

Q37729639-EBA314EB-564B-4CEF-AA55-1D12C355892F

P356

Q37729639-404B2FB2-C472-4200-BC42-2189341EF1E9

P433

Q37729639-902B19F6-8012-4C95-A840-BEA61BCD0F3F

P478

Q37729639-68E1D146-9F23-44B8-8D57-47E37FBCDFFE

P577

Q37729639-CC780354-2C42-43AD-A3B6-E060BC15F473

P698

Q37729639-EABB0735-7C28-415C-93D6-08B9EE2A2324

P921

Q37729639-B6696E6A-47FF-433A-9166-3691D319AF9C

P932

Q37729639-A9A7B1B4-911F-4302-8B7C-7B9E84CDAC4E

P356

P1433

Cellular and Molecular Immunology

P1476

CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

@en

P2093

Dandan Lv

http://www.w3.org/2001/XMLSchema#string

Ha-Jeong Kim

http://www.w3.org/2001/XMLSchema#string

Lixing Zhang

http://www.w3.org/2001/XMLSchema#string

Xiaojing Ma

http://www.w3.org/2001/XMLSchema#string

Yan Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

RFLAT-1: a new zinc finger transcription factor that activates RANTES gene expression in T lymphocytes

Transcription of a novel mouse semaphorin gene, M-semaH, correlates with the metastatic ability of mouse tumor cell lines

Inflammation and cancer

The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

Myeloid-derived suppressor cells as regulators of the immune system

Transcriptional regulation of RANTES expression in T lymphocytes

Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5

Synthetic lethality--a new direction in cancer-drug development

P2888

P304

303-310

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CMI.2012.69

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23376885

http://www.w3.org/2001/XMLSchema#string

P921

P932

4003203

http://www.w3.org/2001/XMLSchema#string